Imunon, Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2024-09-30; filed 2024-11-07.
0001493152-24-043931
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresCurrent report: 10-Q
Period ended 2025-03-31; filed 2025-05-12.
0001641172-25-009572
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 10 previous paragraphs and 8 current paragraphs.
7 unchanged; 0 reworded; 1 added; 3 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
The current filing states there were no material changes to risk factors.
This is the filer’s own statement, not a conclusion from the comparison. Read its qualifications and the report it references.
Current filing’s statement
There have been no material changes to our risk factors from those disclosed under “Risk Factors” in Part I, Item 1A of our 2024 Annual Report on Form 10-K. The risks and uncertainties described in our 2024 Annual Report on Form 10-K are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition, or results of operations.
Added paragraphs (1)
Removed paragraphs (3)
Previous report
On July 30, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”) for a registered direct offering of its common stock, par value $0.01 per share (“Common Stock”). In a concurrent private placement (together with the registered direct offering, the “Offering”) and also pursuant to the Purchase Agreement, the Company issued to the Purchasers unregistered warrants (the “Warrants”)to purchase an aggregate of 5,000,000 shares of Common Stockat an exercise price of $2.00 per share. The Warrants were exercisable immediately for a term of five and one-half years following the date of issuance. The Company received gross proceeds of $10.0 million from the Offering, before deducting placement agent fees and other offering expenses payable by the Company. As of September 30, 2024, no Warrants have been exercised.
Previous report
H.C. Wainwright & Co., LLC acted as the lead placement agent for the Offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent. The Offering closed on August 1, 2024. The Company plans to use the proceeds from the Offering for working capital and general corporate purposes. The Warrants were not and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder, or under any state securities laws. The Company relied on this exemption from registration based in part on representations made by the Purchasers. The Warrants may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Previous report
On August 29, 2024, the Company filed with the SEC aresale registration statement on Form S-1 to register the shares of Common Stock issuable upon the exercise of the Warrants, which resale registration statement was declared effective by the SEC on September 26, 2024.